Conor M. Lane
Cardiologist at Mayo Clinic in Rochester, working in interventional cardiology, and first author of a trial of low-dose rapamycin in frail older adults with heart failure with preserved ejection fraction
Department of Cardiovascular Medicine (Division of Interventional Cardiology), Mayo Clinic, Rochester (2023–2026) · Department of Internal Medicine, Mayo Clinic (2020–2021)
Conor Lane is first author of the Atlas entry LAN2026, a 2026 Mayo Clinic Proceedings report on rapamycin in frail older people who have heart failure with preserved ejection fraction (HFpEF). In HFpEF the heart pumps out a normal share of its blood with each beat but is stiff and fills poorly. It is common in older adults, and there are few treatments that help. Rapamycin, the classic mTOR blocker, slows aging processes in animals, so a trial in this group tests whether that idea carries over to a real age-related disease in people.
The team joined Mayo Clinic cardiologists, including senior author Mandeep Singh, with aging researchers James Kirkland at Mayo and Dudley Lamming and Judith Simcox at the University of Wisconsin-Madison. The abstract was not yet public when the Atlas entry was made, so the results are not summarised here.
Lane's other papers trace a clinical career at Mayo Clinic in Rochester. In 2020 and 2021 PubMed lists the Department of Internal Medicine, on studies of heart ultrasound methods and of medicines linked to microscopic colitis. From 2023 the affiliation is cardiovascular medicine, with case reports and commentary on catheter-based treatments, such as removing infected material from a mitral valve, repairing a coronary aneurysm and opening a blocked bypass graft. By 2025 Lane is listed in the Division of Interventional Cardiology.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2026 | H | Rapamycin in Frail Older Subjects with Heart Failure with Preserved Ejection Fraction LAN2026 First author of the Mayo Clinic and University of Wisconsin report on low-dose rapamycin in frail older adults with HFpEF. |
Co-authors in the Atlas 3
People with a profile here who share at least one study with Conor M. Lane.
ShowHide
- Dudley W. Lamming Showed as a postdoc that rapamycin's harm to glucose metabolism comes largely from its effect on mTORC2, while the lifespan benefit tracks mTORC1. His Wisconsin lab studies intermittent rapamycin dosing and how restricting dietary protein or single amino acids affects metabolism and ageing
- James L. Kirkland Founder of the field of senolytics, drugs that clear senescent cells, and a leader of clinical trials of ageing-targeted therapies
- Mandeep Singh Interventional cardiologist and professor of medicine at Mayo Clinic; corresponding author on a 2026 trial of low-dose rapamycin in frail older adults with heart failure with preserved ejection fraction (HFpEF)
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.